PMID- 35112972
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230403
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 29
IP  - 3
DP  - 2023 Apr
TI  - Poor tolerability of lenvatinib in elderly patients >/=80 years old with 
      hepatocellular carcinoma: A multicenter observational study.
PG  - 626-636
LID - 10.1177/10781552221077039 [doi]
AB  - INTRODUCTION: Management of elderly patients with cancer has become a global 
      issue. We investigated the safety and tolerability of lenvatinib in 
      hepatocellular carcinoma (HCC) patients >/=80 years old. METHODS: We 
      retrospectively evaluated 61 HCC patients and divided them into 2 groups: an 
      elderly group (n = 13, >/=80 years old) and a younger group (n = 48, <80 years 
      old). We compared the adverse events (AEs), administration period, dose 
      intensity, objective response, and progression-free survival (PFS) between the 
      two groups. RESULTS: The discontinuation of lenvatinib due to AEs was more 
      frequent in the elderly group (8/13, 61.5%) than in the younger group (10/48, 
      20.8%) (P = 0.0043). Fatigue and appetite loss accounted for half of the cases 
      discontinued due to AEs in the elderly group. The elderly group had a 
      significantly lower 8-week-delivered dose intensity/body surface area ratio 
      (147.2) and 8-week-relative dose intensity (50.0%) than those in the younger 
      group (267.4, 67%) (P = 0.003, 0.029). The objective response rate was 
      significantly lower in the elderly group (15.4%) than in the younger group 
      (61.5%) (P = 0.021). The PFS in the elderly group tended to be shorter than that 
      in the younger group (P = 0.058, hazard ratio [HR] 1.98). The modified 
      albumin-bilirubin (mALBI) grade (hepatic function) (HR, 2.60; P = 0.01) and 
      objective response (HR, 0.41; P = 0.011) were independently associated with the 
      PFS in the multivariate analysis. CONCLUSION: The management of AEs is crucial 
      for adherence and maintaining the dose intensity of lenvatinib in elderly HCC 
      patients.
FAU - Kinoshita, Akiyoshi
AU  - Kinoshita A
AUID- ORCID: 0000-0002-6546-4485
AD  - Division of Gastroenterology and Hepatology, 38341the Jikei University Daisan 
      Hospital, Komae, Tokyo, Japan.
FAU - Hagiwara, Noriko
AU  - Hagiwara N
AD  - Division of Gastroenterology and Hepatology, 38341the Jikei University Daisan 
      Hospital, Komae, Tokyo, Japan.
FAU - Osawa, Akiyuki
AU  - Osawa A
AD  - Division of Gastroenterology and Hepatology, 38341the Jikei University Daisan 
      Hospital, Komae, Tokyo, Japan.
FAU - Akasu, Takafumi
AU  - Akasu T
AD  - Division of Gastroenterology and Hepatology, 26799the Jikei University Kashiwa 
      Hospital, Kashiwa, Chiba, Japan.
FAU - Matsumoto, Yoshihiro
AU  - Matsumoto Y
AD  - Division of Gastroenterology and Hepatology, 26799the Jikei University Kashiwa 
      Hospital, Kashiwa, Chiba, Japan.
FAU - Ueda, Kaoru
AU  - Ueda K
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Minato, Tokyo, Japan.
FAU - Saeki, Chisato
AU  - Saeki C
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Minato, Tokyo, Japan.
FAU - Oikawa, Tsunekazu
AU  - Oikawa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Minato, Tokyo, Japan.
FAU - Koike, Kazuhiko
AU  - Koike K
AD  - Division of Gastroenterology and Hepatology, 38341the Jikei University Daisan 
      Hospital, Komae, Tokyo, Japan.
FAU - Saruta, Masayuki
AU  - Saruta M
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Minato, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20220203
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Retrospective Studies
MH  - *Antineoplastic Agents/adverse effects
MH  - Phenylurea Compounds/adverse effects
MH  - *Quinolines/adverse effects
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - elderly
OT  - lenvatinib
OT  - tolerability
EDAT- 2022/02/04 06:00
MHDA- 2023/04/03 06:42
CRDT- 2022/02/03 12:15
PHST- 2023/04/03 06:42 [medline]
PHST- 2022/02/04 06:00 [pubmed]
PHST- 2022/02/03 12:15 [entrez]
AID - 10.1177/10781552221077039 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2023 Apr;29(3):626-636. doi: 10.1177/10781552221077039. Epub 
      2022 Feb 3.